Large-cap healthcare companies provide investors with access to innovation, scale, and resilience – key traits in a sector driven by both demographic tailwinds and technological advancement. Are you looking for healthcare companies that combine operational scale with consistent revenue growth and strong balance sheets?
Krystal Biotech develops gene therapies for rare skin diseases, led by its FDA-approved Vyjuvek treatment for dystrophic epidermolysis bullosa patients. Cardinal Health provides pharmaceuticals, medical supplies, and solutions to healthcare providers through pharmaceutical distribution and medical products segments worldwide today. McKesson distributes pharmaceuticals and medical products to thousands of locations, supporting healthcare providers with advanced supply chain solutions and technology.
Together, these large-cap healthcare leaders combine operational excellence with strategic positioning in high-growth markets. From hospitals to distributors, these are among the best large-cap healthcare stocks for 2026.
Roboforex R-Trader gives you access to over 10,000 stocks, ETFs, commodities, and crypto. All of the stocks mentioned in this article are available for purchase there.
Before we dive into each company, let`s take a look at how your investment would have performed if you had invested in stocks mentioned in this article.
The chart below shows how a basket of one share in each company would have performed if bought on the first day shown on the chart.
Now, let`s take a closer look at each of the companies:
Cardinal Health (NYSE:CAH)
Cardinal Health is a multinational healthcare services and products company that provides pharmaceuticals, medical supplies, and solutions to healthcare providers worldwide. The company was founded in 1971 in Dublin, Ohio, originally as Cardinal Foods before shifting its focus to pharmaceutical distribution. Over the years, it has grown into a critical player in the healthcare supply chain, ensuring the efficient delivery of essential medical products.
Cardinal Health operates through two main business segments encompassing pharmaceutical distribution and medical products for healthcare providers across nationwide and international markets. Its pharmaceutical division supplies medications to hospitals, pharmacies, and healthcare facilities, while its medical segment provides surgical supplies, laboratory products, and patient care solutions. With a strong focus on logistics, Cardinal Health helps healthcare providers optimize supply chain efficiency, reduce costs, and improve patient care outcomes.
Cardinal Health financial statements
Financial Health
- Market Cap: $58.83B
- Dividend Yield: 0.81%
- Return on assets (ROA): 3.5%
- Return on equity (ROE): N/A
- Debt-to-Equity: N/A
- Current Ratio: 0.883
Profitability
- Gross margin: 3.69%
- Operating margin: 1.23%
- Net profit margin: 0.68%
- P/E Ratio: 18.070845
- Price-to-Book: N/A
- Quick Ratio: 0.425
Growth & Estimates
- Analysts recommendation: 1.5
- EPS (current): 6.95
- EPS growth (this year): 19.4%
- EPS growth (QoQ): 66.5%
- Sales growth (QoQ): 18.8%
- Beta: 0.501
💡 Why invest in Cardinal Health?
Cardinal Health combines drug distribution scale, hospital relationships, and medical product reach across healthcare markets:
- Critical Supply Chain: As a leading distributor of pharmaceuticals and medical products, Cardinal Health plays an essential role in the healthcare supply chain, ensuring reliable delivery of critical medicines to providers nationwide.
- Revenue Stream Diversification: The company`s pharmaceutical distribution and medical products segments provide diversified revenue streams, reducing reliance on any single market while capturing growth opportunities across healthcare channels.
- Distribution Network Scale: Cardinal Health`s extensive size and scale enable it to leverage its nationwide distribution network effectively, negotiate favorable supplier terms, and achieve significant operational efficiencies across operations.
- Demographic Growth Tailwinds: The healthcare industry continues expanding driven by aging population demographics and rising demand for medical services, creating sustained expansion opportunities for Cardinal Health`s distribution services.
🐌 Key considerations before investing in Cardinal Health
Cardinal Health faces pricing pressure, litigation exposure, supplier concentration, and margin limits in drug distribution:
- Healthcare Policy Uncertainty: The healthcare industry faces heavy regulation with frequent government policy changes impacting reimbursement rates and operational requirements, creating ongoing compliance costs and strategic uncertainty.
- Intense Distribution Competition: The pharmaceutical distribution markets face intense competition from established players like McKesson and Cencora plus new entrants, pressuring margins and requiring continuous technology investment.
- Supply Chain Vulnerability: Cardinal Health faces operational risks from product availability issues, transportation disruptions, and inventory management challenges that can significantly impact business operations and overall profitability.
- Economic Recession Exposure: Economic downturns and healthcare spending reductions can negatively affect demand for medical products, delay hospital capital expenditures, and pressure reimbursement rates for Cardinal Health operations.
Final thoughts on Cardinal Health
Cardinal Health`s role as a healthcare distribution leader with diversified revenue streams and operational scale offers potential advantages for investors seeking exposure. However, the complex regulatory environment, intense competition, supply chain risks, and economic factors necessitate thorough consideration before investing in the company. Thorough research on Cardinal Health`s market share, financial performance, and the overall healthcare industry trends remains crucial before making investment decisions.
McKesson (NYSE:MCK)
McKesson Corporation is a leading healthcare distribution and services company specializing in pharmaceutical supply chain management, medical supplies, and healthcare technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson has grown into one of the largest healthcare companies in the United States, playing a critical. The company serves hospitals, pharmacies, and healthcare providers, helping to streamline operations and improve patient outcomes. supporting balanced exposure and.
With an extensive global distribution network, McKesson delivers pharmaceuticals and medical products to thousands of locations, supporting both independent healthcare providers and large-scale institutions. The company is also a key player in healthcare technology, offering advanced data analytics, automation, and supply chain solutions that enhance efficiency and reduce costs. By continuously innovating and expanding its reach, McKesson remains a vital force in the healthcare industry, ensuring access to essential medicines and improving overall healthcare.
McKesson financial statements
Financial Health
- Market Cap: $117.15B
- Dividend Yield: 0.37%
- Return on assets (ROA): 4.33%
- Return on equity (ROE): N/A
- Debt-to-Equity: N/A
- Current Ratio: 0.893
Profitability
- Gross margin: 3.45%
- Operating margin: 1.54%
- Net profit margin: 1.09%
- P/E Ratio: 19.846367
- Price-to-Book: N/A
- Quick Ratio: 0.504
Growth & Estimates
- Analysts recommendation: 1.6
- EPS (current): 34.64
- EPS growth (this year): 38%
- EPS growth (QoQ): -21.7%
- Sales growth (QoQ): 11.4%
- Beta: 0.298
💡 Why invest in McKesson?
McKesson`s robust profile makes it a tempting pick for investors seeking exposure to the ever-evolving healthcare sector globally:
- Healthcare Distribution Leader: McKesson boasts a leading position in pharmaceutical distribution across North America, delivering a third of all drugs used in the region with predictable revenue streams and expansion potential while maintaining focus.
- Diversified Service Offerings: Recognizing the changing healthcare landscape, McKesson expands beyond traditional drug distribution into medical-surgical supplies, laboratory equipment, and healthcare IT solutions for strategic expansion.
- Digital Technology Integration: McKesson's technology-driven platforms enhance patient care and operational efficiency throughout the ecosystem while maintaining disciplined execution and strong partnerships across the healthcare value chain.
- Broad Geographic Reach: With operations spanning North America and Europe, McKesson caters to a diverse customer base and benefits from significant growth opportunities across various regional healthcare markets while maintaining disciplined execution.
🐌 Key considerations before investing in McKesson
McKesson navigates reimbursement changes, regulatory scrutiny, and margin pressure, requiring disciplined execution, cost control:
- Healthcare Regulatory Complexity: Evolving regulations surrounding drug pricing, healthcare reform, and data privacy can impact McKesson`s operations and necessitate costly compliance measures requiring continuous adaptation strategies.
- Ongoing Legal Challenges: McKesson has faced legal challenges regarding its role in the opioid epidemic, generating negative publicity and potential reputation impact requiring careful monitoring and strategic responses while maintaining discipline.
- Regional Competitor Pressure: Smaller regional players and online pharmacies are vying for market share, challenging McKesson`s dominant position through innovation and competitive pricing strategies requiring vigilance while maintaining focus.
- Industry Dependency Risk: Heavy reliance on pharmaceutical distribution as a primary revenue source creates exposure to industry-specific risks including drug pricing pressures, regulatory changes, and evolving market dynamics affecting the.
Final thoughts on McKesson
McKesson Corporation`s leadership in pharmaceutical distribution, diverse service offerings, and technology integration create compelling opportunities for long-term investors seeking exposure to the essential healthcare supply. However, the evolving regulatory landscape, legal challenges, rising competition, and reliance on other industry players warrant careful consideration of both opportunities and risks. Like a vital artery in the healthcare system, McKesson`s distribution network remains essential to delivering medicines and medical products, positioning it strategically despite ongoing industry.
Teva Pharmaceutical Industries (NYSE:TEVA)
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Tel Aviv, specializing primarily in generic drugs, branded medications, and active pharmaceutical ingredients. Founded in 1901 as a wholesale drug business in Jerusalem, Teva has grown into the world largest generic drug manufacturer globally. The company serves patients in approximately fifty-seven markets with over thirty-six thousand employees worldwide across North America, Europe, and Asia.
Teva branded portfolio includes Austedo for Huntington disease and tardive dyskinesia, Ajovy for migraine prevention, and the legacy Copaxone for multiple sclerosis. The company operates manufacturing facilities across Israel, North America, Europe, Australia, and South America serving millions of patients with affordable medicines. Ongoing research investments support pipeline expansion across specialty and generic medicines for future patients worldwide today with affordable treatment options.
Teva Pharmaceutical Industries financial statements
Financial Health
- Market Cap: $48.4B
- Dividend Yield: 0%
- Return on assets (ROA): N/A
- Return on equity (ROE): N/A
- Debt-to-Equity: 217.79
- Current Ratio: 0.879
Profitability
- Gross margin: N/A
- Operating margin: N/A
- Net profit margin: N/A
- P/E Ratio: 13.453496
- Price-to-Book: 6.2377877
- Quick Ratio: 0.457
Growth & Estimates
- Analysts recommendation: 1.5
- EPS (current): N/A
- EPS growth (this year): N/A
- EPS growth (QoQ): N/A
- Sales growth (QoQ): N/A
- Beta: 0.817
💡 Why invest in Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries combines generic scale, branded specialty medicines, and global manufacturing for investors:
- Global Generic Dominance: As the world largest generic drug manufacturer by volume, Teva benefits from unmatched scale in production, distribution, and regulatory expertise across dozens of international markets and therapeutic categories.
- Branded Drug Pipeline: Key specialty medications including Austedo for neurological disorders and Ajovy for migraine prevention provide higher-margin revenue streams that complement the high-volume generic business model across global markets.
- Manufacturing Footprint Scale: Extensive production facilities spanning five continents enable cost-efficient local manufacturing, rapid market entry for new generics, and resilience against supply chain disruptions in individual regions.
- Cost Pressure Tailwinds: Growing global pressure to reduce healthcare expenditures drives increasing demand for affordable generic alternatives, positioning Teva to benefit from government and insurer cost-containment initiatives for investors.
🐌 Key considerations before investing in Teva Pharmaceutical Industries
Teva Pharmaceutical Industries faces legal liabilities, pricing pressure, debt obligations, and competitive threats across markets:
- Legal Regulatory Exposure: Teva has faced significant legal settlements including price-fixing fines, opioid litigation payments, and antitrust penalties that have materially impacted financial performance and created ongoing legal uncertainty.
- Generic Pricing Erosion: Intense competition among generic manufacturers combined with purchasing consolidation by pharmacy benefit managers creates persistent downward pressure on generic drug prices and profit margins across global markets.
- Debt Burden Concerns: Historical acquisition-driven growth strategies, particularly the Actavis Generics purchase, left Teva with substantial debt levels that constrain financial flexibility and require ongoing deleveraging efforts.
- Brand Patent Cliff: Revenue from legacy branded products faces ongoing competitive threats from biosimilars and newer therapies, requiring continuous pipeline investment to offset declining sales from maturing product lines for investors.
Final thoughts on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries stands as the undisputed global leader in generic pharmaceuticals with a vast manufacturing network and a growing portfolio of branded specialty drugs. The company benefits from structural demand for affordable medications worldwide and scale advantages in generic production across global markets for patients. Investors should carefully weigh the significant legal exposure, debt obligations, and competitive pricing dynamics against the long-term defensive characteristics of the generic drug market.
Welltower (NYSE:WELL)
Welltower operates as a real estate investment trust focused on healthcare properties across the United States and the United Kingdom markets around the world. Founded in 1970 the company invests in seniors housing post acute care and outpatient medical properties across its healthcare real estate segments and markets. Welltower serves a growing tenant base of aging populations requiring healthcare and senior living accommodation services across its various business segments.
The company generates revenue from rental income on its healthcare properties and property management fee services across its various business segments. Welltower benefits from demographic trends with aging populations driving demand for seniors housing and healthcare facilities across its various business segments. The company faces property market cycles regulatory changes in healthcare and rising construction costs across its markets across its various business segments.
Welltower financial statements
Financial Health
- Market Cap: $169.23B
- Dividend Yield: 1.45%
- Return on assets (ROA): N/A
- Return on equity (ROE): N/A
- Debt-to-Equity: 41.375
- Current Ratio: 1.317
Profitability
- Gross margin: N/A
- Operating margin: N/A
- Net profit margin: N/A
- P/E Ratio: 73.8522
- Price-to-Book: 3.6375322
- Quick Ratio: 0.946
Growth & Estimates
- Analysts recommendation: 1.6
- EPS (current): N/A
- EPS growth (this year): N/A
- EPS growth (QoQ): 47.4%
- Sales growth (QoQ): N/A
- Beta: 0.747
💡 Why invest in Welltower?
Welltower leading healthcare senior housing, outpatient properties, aging population demand drivers strategic market positions acro:
- Healthcare Property Focus: Welltower invests in seniors housing and healthcare real estate serving aging population demand across its various business segments and markets for many years going forward in the future period through markets.
- Demographic Demand Driver: The company benefits from aging population trends driving demand for senior living facilities across its various business segments and markets for many years going forward in the future period through conditions.
- Diversified Portfolio Mix: Welltower owns a diversified portfolio across seniors housing outpatient and post acute segments across its various business segments and markets for many years going forward in the future period framework.
- Strong Tenant Relationships: The company works with leading healthcare operators providing stable occupancy across properties across its various business segments and markets for many years going forward in the future period through value.
🐌 Key considerations before investing in Welltower
Welltower faces property market cycles, healthcare regulation changes, and rising construction costs across its properties:
- Healthcare Regulation Risk: Welltower faces regulatory changes affecting healthcare reimbursement and senior housing operations across its various business segments and markets for many years going forward in the future period through future.
- Property Market Cycles: The company is sensitive to real estate market conditions affecting property valuations and rent across its various business segments and markets for many years going forward in the future period through conditions.
- Rate Sensitivity Factor: Welltower`s portfolio is sensitive to interest rate fluctuations that affect property valuations and borrowing costs across its healthcare real estate portfolio markets in the United States and United Kingdom.
- Construction Cost Pressure: The company faces rising costs for development and renovation of healthcare properties across its various business segments and markets for many years going forward in the future period through various economic value.
Final thoughts on Welltower
Welltower is a leading healthcare REIT with senior housing properties and aging population demand drivers across its markets across its various business segments. The company faces property cycles and regulatory changes while benefiting from demographic trends through 2026 and beyond across its various business segments. Welltower offers investors exposure to healthcare real estate with stable rental income and demographic driven demand over many years ahead.
Otsuka Holdings (T:4578)
Otsuka Holdings is a Japanese healthcare company headquartered in Tokyo, with operations spanning pharmaceuticals, nutraceuticals, and consumer health product markets. Founded in 2008, the holding company coordinates Otsuka group businesses with roots in drug development, nutrition, and medical device markets. Its core franchises include central nervous system therapies, renal treatments, oncology products, and functional beverages for customers across global markets.
The company develops prescription medicines, nutraceutical brands, diagnostics, and clinical nutrition products for hospitals, physicians, pharmacies, and everyday consumers worldwide. Its business model combines internal research, clinical trials, manufacturing, licensing partnerships, and branded consumer distribution across Japan and overseas markets. Otsuka focuses on differentiated therapies, patient adherence, and health-related consumer products that can support resilient demand across changing market cycles.
Otsuka Holdings financial statements
Financial Health
- Market Cap: $40.91B
- Dividend Yield: 1.62%
- Return on assets (ROA): N/A
- Return on equity (ROE): N/A
- Debt-to-Equity: 5.873
- Current Ratio: 2.207
Profitability
- Gross margin: N/A
- Operating margin: N/A
- Net profit margin: N/A
- P/E Ratio: N/A
- Price-to-Book: 1.9979713
- Quick Ratio: 1.441
Growth & Estimates
- Analysts recommendation: 1.8
- EPS (current): N/A
- EPS growth (this year): N/A
- EPS growth (QoQ): 32.5%
- Sales growth (QoQ): N/A
- Beta: -0.022
💡 Why invest in Otsuka Holdings?
Otsuka Holdings combines drug franchises, nutrition brands, and research capabilities across Japan and global healthcare markets:
- Psychiatry Franchise Depth: Otsuka maintains positions in central nervous system medicines, giving the company specialist relationships, differentiated prescribing channels, and experience managing complex patient needs across major markets.
- Healthcare Portfolio Breadth: Pharmaceuticals, nutraceuticals, medical devices, and consumer health products create multiple revenue streams, reducing reliance on one therapy area while broadening customer reach across care settings.
- Research Pipeline Discipline: Internal discovery, clinical development, and licensing partnerships support a steady pipeline approach, helping Otsuka target unmet needs while managing development risk across therapeutic areas and programs.
- Consumer Brand Resilience: Nutrition and wellness brands add recurring demand outside prescription medicines, giving Otsuka defensive cash flow support and wider brand recognition among everyday healthcare consumers and pharmacy channels.
🐌 Key considerations before investing in Otsuka Holdings
Otsuka Holdings depends on clinical execution, patent protection, pricing access, and currency stability across healthcare markets:
- Patent Cycle Exposure: Key medicines can face patent cliffs, generic competition, and portfolio replacement pressure, making Otsuka dependent on launches and lifecycle management to protect specialty drug revenue across important markets.
- Clinical Development Risk: Drug development requires expensive trials, regulatory review, and uncertain safety outcomes, so failed programs can reduce pipeline value and delay growth in priority therapeutic areas for years after investment.
- Pricing Policy Pressure: Healthcare systems and insurers can push for lower drug prices, reimbursement limits, and access controls, pressuring margins even when Otsuka maintains strong clinical positioning across specialty categories.
- Currency Translation Volatility: A global cost base and Japanese reporting currency expose earnings to exchange-rate swings, which can distort overseas revenue, procurement costs, reported profitability, and planning decisions across regions.
Final thoughts on Otsuka Holdings
Otsuka offers diversified healthcare exposure through specialty medicines, nutrition brands, research capabilities, and global commercial reach across multiple patient categories. Patent cycles, clinical trial execution, pricing pressure, and currency swings can still create uneven results across reporting periods and markets. For investors seeking Japanese healthcare exposure, Otsuka suits portfolios that can tolerate pharmaceutical development risk and reimbursement uncertainty over time.
Cencora (NYSE:COR)
Cencora is a global pharmaceutical services company that specializes in drug distribution, consulting, and supply chain solutions for healthcare providers and manufacturers. Founded in 2001 as AmerisourceBergen through the merger of AmeriSource Health and Bergen Brunswig, the company rebranded to Cencora to reflect its evolving global presence. Headquartered in Conshohocken, Pennsylvania, Cencora has become one of the largest pharmaceutical distributors in the world, playing a crucial role in ensuring access to essential.
The company provides a wide range of services, including specialty drug distribution, pharmacy management, and consulting solutions for biotech and pharmaceutical firms. With a strong focus on innovation, Cencora leverages data-driven insights and advanced logistics to enhance supply chain efficiency and improve patient outcomes. By working closely with healthcare providers, manufacturers, and pharmacies, Cencora continues to strengthen its position as a critical partner in the global healthcare ecosystem.
Cencora financial statements
Financial Health
- Market Cap: $65.06B
- Dividend Yield: 0.7%
- Return on assets (ROA): 3.33%
- Return on equity (ROE): 133.47%
- Debt-to-Equity: 446.516
- Current Ratio: 0.935
Profitability
- Gross margin: 3.61%
- Operating margin: 1.18%
- Net profit margin: 0.5%
- P/E Ratio: 17.258986
- Price-to-Book: 21.323494
- Quick Ratio: 0.477
Growth & Estimates
- Analysts recommendation: 1.8
- EPS (current): 8.32
- EPS growth (this year): 14.8%
- EPS growth (QoQ): 11.1%
- Sales growth (QoQ): 5.5%
- Beta: 0.581
💡 Why invest in Cencora?
Cencora`s robust profile presents a compelling case for investors seeking exposure to the evolving healthcare distribution sector:
- Pharmaceutical Distribution Powerhouse: Cencora boasts a commanding presence in the US pharmaceutical distribution landscape, serving a vast network of healthcare providers and pharmacies with consistent volume and predictable revenue streams.
- Value-Added Service Expansion: Recognizing the shifting healthcare landscape, Cencora diversifies its offerings with clinical trial logistics, specialty drug distribution, and data analytics solutions for strategic growth while maintaining discipli.
- International Logistics Network: Cencora's integrated logistics network spans key international markets with burgeoning healthcare demands while maintaining distribution excellence and regulatory compliance across all operating regions globally.
- Technology Innovation Leader: The company's data analytics and digital platforms enhance supply chain visibility across the evolving healthcare landscape while maintaining disciplined execution and strong client engagement worldwide.
🐌 Key considerations before investing in Cencora
Like navigating complex market conditions, Cencora faces headwinds requiring careful consideration from investors carefully:
- Stock Valuation Levels: Like many established healthcare companies, COR`s stock currently sits near multi-year highs, which might limit immediate gains requiring a cautious approach with a patient long-term perspective while maintaining disciplined.
- Pharmaceutical Regulatory Environment: Evolving healthcare regulations and reimbursement challenges can impact Cencora`s profitability and operational efficiency, requiring close monitoring of regulatory changes and their potential impacts.
- Distribution Market Competition: Intense competition from other large distributors and emerging direct-to-provider models pressures margins and requires continuous investment to maintain its competitive edge while sustaining profitable growth.
- Macroeconomic Cycle Vulnerability: Healthcare spending can be impacted by economic downturns, potentially hitting Cencora`s business volume and profitability while requiring monitoring of broader economic trends and potential fluctuations.
Final thoughts on Cencora
Cencora`s distribution dominance, value-added services, global expansion, and technology innovation create compelling opportunities for long-term investors seeking exposure to the essential pharmaceutical distribution sector. However, near-peak valuation levels, regulatory uncertainties, intense market competition, and economic cycle sensitivity warrant careful consideration of both growth potential and inherent risks. Like a vital circulatory system delivering life-saving medications throughout the healthcare ecosystem, Cencora`s strategic positioning and operational excellence make it a critical infrastructure player despite.
Exelixis (NASDAQ:EXEL)
Exelixis Inc. is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative cancer therapies, with a particular emphasis on precision medicine and targeted oncology treatments. Founded in 1994 and headquartered in Alameda, California, the company has evolved from a genomics research organization into a fully integrated oncology-focused pharmaceutical company with multiple approved drugs and a robust pipeline. The company has demonstrated strong commercial success with its flagship drug Cabometyx and strategic partnerships, particularly benefiting from growing demand for targeted cancer therapies and personalized medicine approaches in oncology treatment.
The company`s core business revolves around developing and commercializing small molecule therapies that target specific pathways involved in cancer growth and progression, with Cabometyx serving as the primary revenue driver for advanced renal cell carcinoma and hepatocellular carcinoma treatments. Exelixis maintains an active research and development program focused on expanding Cabometyx`s indications, developing combination therapies, and advancing early-stage oncology compounds through clinical trials. With rising global cancer incidence and increasing adoption of precision medicine, Exelixis is strategically positioned to capitalize on the growing oncology market while expanding its therapeutic portfolio through internal development and strategic collaborations with major pharmaceutical partners.
Exelixis financial statements
Financial Health
- Market Cap: $15.42B
- Dividend Yield: 0%
- Return on assets (ROA): 19.26%
- Return on equity (ROE): 35.53%
- Debt-to-Equity: 8.999
- Current Ratio: 3.456
Profitability
- Gross margin: 96.39%
- Operating margin: 39.41%
- Net profit margin: 33.73%
- P/E Ratio: 14.56013
- Price-to-Book: 8.400378
- Quick Ratio: 3.244
Growth & Estimates
- Analysts recommendation: 2.3
- EPS (current): 2.78
- EPS growth (this year): 84.2%
- EPS growth (QoQ): 14.7%
- Sales growth (QoQ): 5.6%
- Beta: 0.466
💡 Why invest in Exelixis?
466 presents fundamental strengths that position it well for investors seeking stable returns and growth prospects:
- Cabometyx Commercial Success: Exelixis` flagship drug Cabometyx has achieved strong commercial success in multiple cancer indications, generating substantial revenue growth and establishing the company as a leader in targeted treatments.
- Robust Pipeline Expansion: The company maintains a robust development pipeline with multiple clinical trials exploring Cabometyx combinations and new oncology compounds, providing opportunities for label expansions.
- Strategic Partnership Network: Exelixis has established valuable partnerships with major pharmaceutical companies including Roche and Ipsen, providing additional revenue through licensing agreements and shared development costs.
- Specialized Oncology Focus: The company`s specialized focus on cancer therapeutics allows for deep expertise in oncology drug development and regulatory pathways, creating competitive advantages in this therapeutic area.
🐌 Key considerations before investing in Exelixis
Exelixis must manage regulatory review, reimbursement pressure, development risk, and pricing scrutiny through business cycles:
- Revenue Concentration Risk: Heavy reliance on Cabometyx for the majority of revenue creates concentration risk, with potential vulnerability to generic competition or competitive threats that could significantly impact performance.
- Clinical Development Risk: Biopharmaceutical development involves inherent risks of clinical trial failures and unexpected safety issues that could delay or prevent new drug approvals and pipeline advancement.
- Intense Oncology Competition: The oncology market faces intense competition from large pharmaceutical companies and emerging immunotherapy treatments, potentially limiting market share and pricing power for existing products.
- Regulatory Approval Challenges: Operating in the highly regulated pharmaceutical industry exposes Exelixis to potential FDA approval delays and changing regulatory requirements that could impact product commercialization.
Final thoughts on Exelixis
Exelixis` commercial success with Cabometyx, robust development pipeline, and strategic partnerships create compelling opportunities for investors seeking exposure to the growing precision oncology market. However, the company`s drug concentration risks, clinical development uncertainties, competitive pressures, and regulatory challenges require careful evaluation of the complex dynamics in biopharmaceutical markets. Like a skilled oncologist who combines cutting-edge science with patient-focused care, Exelixis leverages its deep cancer expertise and targeted therapy approach to deliver innovative treatments while building sustainable value for shareholders in the evolving healthcare landscape.
Gilead Sciences (NYSE:GILD)
Gilead Sciences Inc. is a leading biopharmaceutical company specializing in antiviral and oncology therapies for patients worldwide, headquartered in Foster City, California. Founded in 1987, Gilead has become a global leader in developing innovative treatments for life-threatening diseases across therapeutic areas globally and in multiple markets. The company maintains strong market positions across HIV, hepatitis, and oncology therapeutic areas while focusing on research and development to advance therapeutic solutions globally.
Gilead`s core business encompasses a diverse portfolio of therapies targeting HIV, hepatitis B and C, and various cancers for patients. Gilead`s flagship HIV treatment Biktarvy leads the market while oncology products like Yescarta and Trodelvy are gaining traction, providing diversified revenue streams across therapeutic areas. The company is advancing its pipeline with promising candidates such as lenacapavir for HIV prevention and seladelpar for liver diseases worldwide.
Gilead Sciences financial statements
Financial Health
- Market Cap: $193.67B
- Dividend Yield: 2.1%
- Return on assets (ROA): 12.52%
- Return on equity (ROE): 40.66%
- Debt-to-Equity: 223.465
- Current Ratio: 1.265
Profitability
- Gross margin: 78.84%
- Operating margin: 37.4%
- Net profit margin: 28.9%
- P/E Ratio: 15.708427
- Price-to-Book: 16.385859
- Quick Ratio: 0.902
Growth & Estimates
- Analysts recommendation: 1.7
- EPS (current): 6.79
- EPS growth (this year): 23.5%
- EPS growth (QoQ): 142.22%
- Sales growth (QoQ): 4.7%
- Beta: 0.332
💡 Why invest in Gilead Sciences?
Gilead Sciences presents fundamental strengths that position it well for investors seeking stable returns and expansion prospects:
- Proven Treatment Portfolio: Gilead`s established treatments in HIV and hepatitis provide a stable revenue base with flagship drug Biktarvy continuing to lead in sales, generating consistent cash flows for ongoing R&D investments and future expansion.
- Next-Generation Pipeline Innovation: The company is investing in next-generation therapies including long-acting HIV prevention drug lenacapavir and novel oncology treatments like Trodelvy, expanding addressable markets and expansion opportunities.
- Targeted Acquisition Strategy: Recent acquisitions like CymaBay Therapeutics aim to bolster Gilead`s presence in liver diseases and other therapeutic areas, diversifying the portfolio and reducing reliance on existing HIV franchise revenues.
- Strong Financial Fundamentals: Gilead maintains robust gross margins of 78.7% and operating margins of 45.2%, demonstrating strong pricing power and operational efficiency that support sustained profitability and attractive shareholder returns.
🐌 Key considerations before investing in Gilead Sciences
Gilead Sciences must manage clinical timelines, reimbursement pressure, regulatory review, and product adoption risk over cycles:
- Acquisition-Related Earnings Volatility: Significant charges from acquisitions have led to fluctuations in net income with recent earnings declining sharply to $480 million, creating near-term financial performance uncertainty for investors.
- Healthcare Policy Risks: Potential changes in healthcare policies such as cuts to HIV prevention funding or drug pricing reforms could significantly impact revenues and profitability across Gilead`s core therapeutic franchises and future growth.
- Competitive Therapeutic Landscape: The biopharmaceutical industry faces intense competition with rivals developing similar therapies that could challenge Gilead`s market share in HIV, hepatitis, and oncology, pressuring pricing and margins.
- Patent Expiration Exposure: Key products face patent expirations in coming years which could lead to generic competition and revenue erosion, requiring successful pipeline execution to offset declining sales from mature franchises worldwide.
Final thoughts on Gilead Sciences
Gilead Sciences maintains a strong position in antiviral and oncology treatments, supported by a robust product portfolio and a pipeline of innovative therapies. While recent financial performance has been affected by acquisition-related charges, the company`s strategic investments and ongoing research efforts position it for potential long-term growth. The company benefits from its established market leadership in HIV treatments and promising oncology pipeline developments that provide a solid foundation for future expansion.
Orion Oyj (HE:ORNBV)
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary medicines and active pharmaceutical ingredients. Founded in 1917 and headquartered in Espoo, Finland, the company sells products in more than one hundred countries through its own network and partners. Its A and B shares trade on Nasdaq Helsinki, with the liquid B share class carrying the bulk of daily turnover.
The global business spans Innovative Medicines, Branded Products, Generics and Consumer Health, Animal Health, and the Fermion specialty ingredients unit. Growth is led by the prostate cancer drug Nubeqa, developed with Bayer, alongside respiratory and Parkinson portfolios and a deepening oncology pipeline. In 2026 the company raised its full-year outlook after a prior year, while advancing pain and cancer candidates and expanding research in Cambridge and Boston.
Orion Oyj financial statements
Financial Health
- Market Cap: $13.84B
- Dividend Yield: 2.05%
- Return on assets (ROA): N/A
- Return on equity (ROE): N/A
- Debt-to-Equity: 10.458
- Current Ratio: 2.639
Profitability
- Gross margin: N/A
- Operating margin: N/A
- Net profit margin: N/A
- P/E Ratio: 18.46584
- Price-to-Book: 9.735789
- Quick Ratio: 1.483
Growth & Estimates
- Analysts recommendation: 2.2
- EPS (current): N/A
- EPS growth (this year): N/A
- EPS growth (QoQ): 69.9%
- Sales growth (QoQ): N/A
- Beta: 0.28
💡 Why invest in Orion Oyj?
Orion Oyj pairs Nubeqa-driven growth with a diversified pharma portfolio and shareholder-friendly distributions across cycles:
- Nubeqa Growth Engine: The prostate cancer franchise developed with Bayer keeps beating expectations, funding research and distributions while carrying credible potential to become a dominant long-term revenue pillar across global markets.
- Diversified Business Mix: Branded medicines, generics, consumer health, animal health, and ingredient manufacturing balance high-growth innovation with stable cash-generating franchises across regions and through full economic periods.
- Research Pipeline Depth: Oncology and pain programs plus biologics expansion and new research centers create multiple shots at follow-on blockbusters beyond the current flagship product, spanning small molecules and emerging biologics.
- Disciplined Capital Returns: A policy of annually rising dividends with a high payout range, buybacks for incentive plans, and a strong equity ratio reward shareholders while funding sustained expansion and pipeline investment across cycles.
🐌 Key considerations before investing in Orion Oyj
Orion Oyj faces partner dependence, patent cliffs, and research attrition inherent to mid-sized innovative pharma companies:
- Partner Concentration Risk: A large share of growth depends on Bayer-led sales of the flagship cancer drug, so royalty terms, partner execution, or competitive entries can quickly reshape the earnings outlook and planned investment capacity.
- Patent Expiry Pressure: Legacy branded and generic franchises face erosion from cheaper rivals once protections lapse, forcing constant renewal of the portfolio to defend revenue as low-cost rivals capture share after protections lapse.
- Clinical Attrition Exposure: Oncology and pain candidates can fail late in costly trials, wiping out years of investment and delaying the next expansion wave the market already anticipates while consuming budgets that could fund other programs.
- Small-Cap Scale Limits: As a mid-sized player, Orion competes for talent, partnerships, and commercial reach against pharmaceutical giants with deeper pipelines, far larger sales forces, and balance sheets that easily absorb clinical setbacks.
Final thoughts on Orion Oyj
Orion Oyj pairs a breakout oncology franchise with a diversified Nordic pharma platform spanning branded, generic, animal, and ingredient businesses. Record recent results and a raised outlook support the growth narrative, while partner dependence and clinical risk require ongoing monitoring. For long-term investors seeking European pharma exposure, Orion offers innovation-led growth with consistent steady shareholder distributions plus underappreciated pipeline optionality.
United Therapeutics (NYSE:UTHR)
United Therapeutics is a biotechnology company specializing in the development and commercialization of innovative therapies for pulmonary hypertension and other life-threatening diseases. Founded in 1996 and headquartered in Silver Spring, Maryland, the company was established with a mission to address unmet medical needs through cutting-edge science. United Therapeutics has grown into a leading player in the biotech sector, leveraging advanced technologies to improve patient outcomes worldwide.
The company is best known for its successful treatments for pulmonary arterial hypertension, including the widely prescribed Remodulin, Tyvaso, and Orenitram therapies. Beyond pulmonary hypertension, United Therapeutics actively develops innovative organ transplantation solutions, including 3D-printed organs and advanced xenotransplantation technologies for patients. By combining deep innovation with commitment to addressing rare and serious conditions, the company pushes the boundaries of biotechnology to extend lives.
United Therapeutics financial statements
Financial Health
- Market Cap: $22.87B
- Dividend Yield: 0%
- Return on assets (ROA): 13.14%
- Return on equity (ROE): 20.04%
- Debt-to-Equity: N/A
- Current Ratio: 5.732
Profitability
- Gross margin: 88.59%
- Operating margin: 48.69%
- Net profit margin: 40.65%
- P/E Ratio: 15.373763
- Price-to-Book: 3.5548208
- Quick Ratio: 4.891
Growth & Estimates
- Analysts recommendation: 1.9
- EPS (current): 26.39
- EPS growth (this year): 12.1%
- EPS growth (QoQ): 7.6%
- Sales growth (QoQ): 6.8%
- Beta: 0.49
💡 Why invest in United Therapeutics?
United Therapeutics demonstrates key advantages that make it an attractive investment in the specialized biotechnology sector:
- Rare Disease Specialization: The company primarily targets rare and life-threatening diseases with limited treatment options, creating high unmet medical needs and premium pricing opportunities that generate exceptionally strong profit margins.
- First-Mover Treatment Advantage: United Therapeutics has successfully developed and commercialized several first-in-class therapies for pulmonary arterial hypertension, providing significant competitive advantages through market leadership.
- Regenerative Medicine Pipeline: While pulmonary arterial hypertension remains the core focus, the company actively expands into organ transplantation and regenerative medicine including 3D-printed organs and xenotransplantation technologies.
- Robust Intellectual Property: United Therapeutics maintains a comprehensive patent portfolio protecting its innovative products and manufacturing processes, creating substantial barriers to entry for competitors and extending revenue streams.
🐌 Key considerations before investing in United Therapeutics
United Therapeutics must manage regulatory review, reimbursement pressure, development risk, and pricing scrutiny over cycles:
- Rare Disease Competition: The biotechnology industry faces intense competition from numerous well-funded companies developing treatments for similar rare diseases, creating meaningful risks of market share erosion and pricing pressure.
- Complex Regulatory Challenges: Drug development and approval processes involve complex regulatory requirements subject to frequent changes, which can significantly impact product development timelines and commercialization strategies.
- Clinical Trial Volatility: The biotechnology sector experiences significant stock price volatility with shares fluctuating dramatically based on clinical trial results, regulatory approval decisions, and broader market sentiment shifts.
- Product Concentration Dependency: While United Therapeutics pursues pipeline diversification, its commercial success remains heavily dependent on the continued strong performance of its core pulmonary arterial hypertension product portfolio.
Final thoughts on United Therapeutics
United Therapeutics` deep focus on orphan diseases and innovative pipeline expansion create compelling opportunities for long-term investors seeking specialized biotechnology exposure. However, investors must carefully weigh intense competition, complex regulatory challenges, sector volatility, and significant product concentration risks in this specialized space. United Therapeutics offers transformative growth potential that is balanced against the inherent uncertainties of biotechnology innovation and ongoing drug commercialization efforts.
For regional views of this theme, see best European large cap healthcare stocks.
For related regional views, see best International or Nordic healthcare stocks.
To compare market-cap segments within healthcare, see best mega, mid, or small cap stocks.
For the same large cap segment, see best AI, automotive, basic materials, beauty, brokers, cloud, communication services, or conglomerate stocks.
For income-focused variants, see best large cap healthcare dividend, healthcare dividend, large cap dividend, or dividend stocks.